BBR Partners LLC Increases Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

BBR Partners LLC increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 74.1% during the 3rd quarter, Holdings Channel reports. The firm owned 470,000 shares of the biopharmaceutical company’s stock after acquiring an additional 200,000 shares during the period. BBR Partners LLC’s holdings in Lexicon Pharmaceuticals were worth $738,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. FMR LLC increased its stake in Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after purchasing an additional 3,536,805 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $3,871,000. Marshall Wace LLP lifted its holdings in Lexicon Pharmaceuticals by 138.5% in the 2nd quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company’s stock worth $2,000,000 after purchasing an additional 691,276 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $912,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on LXRX shares. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Stock Down 1.9 %

Shares of LXRX opened at $0.80 on Thursday. The business’s 50 day simple moving average is $1.48 and its 200-day simple moving average is $1.68. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.73 and a 1 year high of $3.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock has a market capitalization of $198.20 million, a price-to-earnings ratio of -1.07 and a beta of 1.24.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $3.14 million. During the same period in the previous year, the company earned ($0.21) EPS. As a group, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.